* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Plasmodium falciparum enolase - Tata Institute of Fundamental
Lipid signaling wikipedia , lookup
Biosynthesis wikipedia , lookup
Biochemistry wikipedia , lookup
Ultrasensitivity wikipedia , lookup
Interactome wikipedia , lookup
Amino acid synthesis wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Ancestral sequence reconstruction wikipedia , lookup
Clinical neurochemistry wikipedia , lookup
Evolution of metal ions in biological systems wikipedia , lookup
Point mutation wikipedia , lookup
Enzyme inhibitor wikipedia , lookup
Magnesium transporter wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Expression vector wikipedia , lookup
Homology modeling wikipedia , lookup
Proteolysis wikipedia , lookup
Protein structure prediction wikipedia , lookup
Metalloprotein wikipedia , lookup
Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup
Protein purification wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Eur. J. Biochem. 271, 4845–4854 (2004) FEBS 2004 doi:10.1111/j.1432-1033.2004.04450.x Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase Ipsita Pal-Bhowmick, K. Sadagopan, Hardeep K. Vora, Alfica Sehgal*, Shobhona Sharma and Gotam K. Jarori Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, India We have cloned, over-expressed and purified enolase from Plasmodium falciparum strain NF54 in Escherichia coli in active form, as an N-terminal His6-tagged protein. The sequence of the cloned enolase from the NF54 strain is identical to that of strain 3D7 used in full genome sequencing. The recombinant enolase (r-Pfen) could be obtained in large quantities ( 50 mg per litre of culture) in a highly purified form (> 95%). The purified protein gave a single band at 50 kDa on SDS/PAGE. MALDI-TOF analysis gave a mean ± SD mass of 51396 ± 16 Da, which is in good agreement with the mass calculated from the sequence. The molecular mass of r-Pfen determined in gel-filtration experiments was 100 kDa, indicating that P. falciparum enolase is a homodimer. Kinetic measurements using 2-phosphoglycerate as substrate gave a specific activity of 30 UÆmg)1 and Km2PGA ¼ 0.041 ± 0.004 mM. The Michaelis constant for the reverse reaction (KmPEP) is 0.25 ± 0.03 mM. pH-dependent activity measurements gave a maximum at pH 7.4–7.6 irrespective of the direction of catalysis. The activity of this enzyme is inhibited by Na+, whereas K+ has a slight activating effect. The cofactor Mg2+ has an apparent activation constant of 0.18 ± 0.02 mM. However, at higher concentrations, it has an inhibitory effect. Polyclonal antibody raised against pure recombinant P. falciparum enolase in rabbit showed high specificity towards recombinant protein and is also able to recognize enolase from the murine malarial parasite, Plasmodium yoelii, which shares 90% identity with the P. falciparum protein. Malaria remains one of the most infectious diseases in the third world with about 500 million infections and over one million deaths per year [1]. In the face of increasing threats by resurgent infections and an expanding array of drugresistant phenotypes, the requirement of alternative preventive therapeutics is evident, especially for the most severe form of human malaria parasite Plasmodium falciparum. The first step in rational drug development involves identification of macromolecular targets, which are unique and essential for the survival of the parasite. Glycolytic enzymes seem to be promising candidates from this perspective, as energy production in P. falciparum depends entirely on the glycolytic pathway as the parasite and its mammalian host (red cells) lack a complete Krebs cycle and active mitochondria [2,3]. The level of glycolytic flux in parasite-infected cells is 100-fold greater than that observed in uninfected cells, and the activity of many of the glycolytic enzymes is higher in the infected cells than in uninfected ones [4]. Therefore an antimalarial that selectively inhibits the parasite ATP-generating machinery would be expected to arrest parasite development and growth. Extensive work has already been carried out with many P. falciparum glycolytic enzymes, with aldolase, lactate dehydrogenase and triose phosphate isomerase showing quite promising behavior as detection tools, drug targets and vaccine candidates [5–8]. P. falciparum enolase (Pfen) (EC 4.2.1.11), the dehydrating glycolytic metalloenzyme that catalyzes the inter conversion of 2-phosphoglyceric acid (2-PGA) and phosphoenolpyruvate (PEP), has not yet been characterized. Enolases are highly conserved across species [9]. In most species, it exists as a symmetric homodimer [10]. However, in several bacterial species, octameric enolases have been reported [11,12]. Conservation is particularly pronounced for the active-site residues, leading to similar kinetic properties among enolases from diverse sources. For activity, enolase requires the binding of 2 mol bivalent cations (in vivo this is usually Mg2+) per subunit. Binding at site I leads to changes in the tertiary structure of the enzyme (conformational site) whereas binding to site II is essential for catalysis (catalytic site) [13]. At higher concentrations, bivalent cations inhibit activity, suggesting the existence of a third inhibitory site. Univalent cations also influence the activity of enolases. Most of the enolases are inhibited by Na+, whereas the effect of K+ depends on the source of the enzyme. K+ has no effect on yeast enolase whereas it activates rabbit enolases [14]. Correspondence to G. K. Jarori, Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400 005, India. Fax: +91 22 2280 4610, Tel.: +91 22 2280 4545, E-mail: [email protected] Abbreviations: DAPI, 4¢,6¢-diamidinophenylindole; PEP, phosphoenolpyruvate; 2-PGA, 2-phosphoglyceric acid; r-Pfen, recombinant Plasmodium falciparum enolase. Enzyme: enolase (EC 4.2.1.11). *Present address: Section of Infectious Diseases/Internal Medicine, Yale University, New Haven, CT 06511, USA. (Received 4 September 2004, accepted 22 October 2004) Keywords: enolase; homodimer; localization; Plasmodium falciparum; purification. FEBS 2004 4846 I. Pal-Bhowmick et al. (Eur. J. Biochem. 271) There have been reports of antibodies to enolase detected in high titers in Japanese and Thai P. falciparum patient sera and use of yeast enolase for immunodiagnostic purposes [15]. The activity of enolase in parasite-infected red blood cells increases 15-fold [16]. The gene for P. falciparum (strain K1) enolase (Pfen) has been cloned and characterized [17]. However, Pfen protein has not yet been characterized. The deduced sequence of Pfen exhibits high homology with mammalian enolases (68–69%), but differs in containing a plant-like pentapeptide (EWGWS), a dipeptide insertion, and some different residues [17]. These include Cys157. The analogous residue in Trypanosoma brucei enolase (Cys147) has recently been shown to be modified with iodoacetamide [18,19]. Reaction with iodoacetamide also leads to partial inactivation of the enzyme. It will be interesting to examine whether modification of Cys157 and other P. falciparumspecific residues in the vicinity of the active site leads to irreversible inactivation of Pfen. Comparative studies on the structural and kinetic properties of parasitic and mammalian enolases may provide clues for obtaining specific inhibitors that can be developed as chemotherapeutic reagents. To address questions related to the detailed characterization of the molecular structure and kinetic properties and to develop immunological reagents for subcellular localization, we cloned Pfen and over-expressed it in Escherichia coli to obtain adequate quantities of pure recombinant P. falciparum enolase (r-Pfen). The results of these experiments are presented in this paper. Materials and methods Materials Taq DNA polymerase, T4 DNA ligase, endonucleases (KpnI and PstI), 4¢,6¢-diamidinophenylindole (DAPI) and 2,2¢-azinobis(3-ethylbenzo-6-thiazolinesulfonic acid) powder were purchased from Roche Diagnostics Corp. (Indianapolis, IN, USA). Mouse anti-His sera were from Qiagen, Hilden, Germany. Horseradish peroxidase-conjugated anti-mouse secondary IgG was obtained from Santa Cruz Biotech (Santa Cruz, CA, USA), and Coomassie Brilliant Blue R-250 was acquired from USB (Cleveland, OH, USA). Nitrocellulose membrane, dithiothreitol, molecular mass markers used for gel filtration and Superdex-75 HiLoad 16/60 (Prep grade) column were from Amersham Pharmacia. Oligonucleotide primers, dianilinobenzene, sodium salt of 2-PGA, rabbit muscle enolase (b-isoform), yeast enolase, iodoacetamide, N-ethylmaleimide and unstained high molecular mass protein markers for gel electrophoresis were purchased from Sigma, St Louis, MO, USA. Freund’s complete and incomplete adjuvants were from Gibco-BRL, Alexa Fluor 488-conjugated anti-rabbit IgG was from Molecular Probes, Inc. (Eugene, OR, USA), and vectashield-mounting medium was from Vector Laboratories, Inc. (Burlingame, CA, USA). Maxisorp plates for ELISA were from Nunc, Roskilde, Denmark. All other chemicals used in this study were of analytical grade. PCR amplification Sense and antisense primers were designed according to the multiple cloning sites present in the pQE30 expression vector and the published sequence of the P. falciparum enolase gene [17]. The two primers were: PfenoEcoRIKpnI (32-mer) 5¢-CCGGAATTCGGTACCATGGCTCATGT AATAAC-3¢ and PfenoPstIXhoI (30-mer) 5¢-CATTCT CGAGCTGCAGATTTAATTGTAATC-3¢. A gametocytic cDNA library constructed from the NF54 strain was used for the amplification of the enolase gene (cDNA library used here was a gift from N. Kumar, Johns Hopkins University, Baltimore, MD, USA). Amplification was carried out in the standard Robocycler Gradient Stratagene machine (Stratagene, La Jolla, CA, USA) in a reaction consisting of 400 ng of each of the primers, 100 lM dNTP mix, pH 8.8 buffer, 2 mM MgCl2, 50 mM KCl, 0.01% gelatin, 2 U Taq polymerase and 2 lL of the template library in a final volume of 20 lL. The amplified enolase PCR product and the pQE30 plasmid vector were digested with KpnI and PstI restriction enzymes, and these were ligated using T4 ligase. Competent XL1Blue E. coli cells were transformed with the ligation mixture to obtain the required recombinants, which were screened by PCR and plasmid DNA preparation, and finally sequencing was performed (Macrogen Inc., Seoul, South Korea) using standard protocols [20]. Expression in E. coli and preparation of crude cellular extracts Expression was carried out in E. coli strain XL1Blue. Cultures transformed with recombinant plasmid were grown in Luria–Bertani medium containing 100 lgÆmL)1 ampicillin. Cultures were induced with 0.5 mM isopropyl thio-b-D-galactoside. Before induction, cultures were grown at 37 C to an A600 of 0.6–0.8. For analytical studies, culture aliquots were taken at different time intervals (0, 3, 4, 5, 6 h) after the induction and analyzed for protein production. The cells were pelleted by centrifugation at 5000 g for 10 min and stored at )80 C. The cells were lysed by incubation in 50 mM sodium phosphate (10 mL per g wet weight), pH 8.0, containing 300 mM NaCl, 1 mgÆmL)1 lysozyme and 1 mM phenylmethanesulfonyl fluoride for 30 min on ice and sonicated for six cycles, 15 s each with 15 s cooling between successive bursts at 5 output in a Branson sonifier 450. The lysate was centrifuged at 45 000 g for 30 min in a Beckman Ultracentrifuge (model LE-80K, 70 Ti rotor). Affinity chromatography His6-tagged r-Pfen was purified from soluble cell extract using Ni-nitrilotriacetic acid affinity chromatography. The binding was carried out by the batch method. Soluble cell extract was mixed with Ni-nitrilotriacetic acid (pre-equilibrated with 50 mM sodium phosphate, pH 8.0, 300 mM NaCl) slurry (8 mL per litre of culture) for 1 h with gentle agitation. The slurry was passed through a column and washed with 50 bed vols 50 mM sodium phosphate, 40 mM imidazole, 300 mM NaCl, 1 mM phenylmethanesulfonyl fluoride, 5 mM 2-mercaptoethanol, pH 6.0, to remove nonspecifically bound proteins. r-Pfen was eluted with 250 mM imidazole in the same buffer. FEBS 2004 Characterization of P. falciparum enolase (Eur. J. Biochem. 271) 4847 The oligomeric state of r-Pfen was analyzed by gel-filtration chromatography on a Superdex-75 Hiload-16/60 column on an Amersham-Pharmacia Biotech (Kwai Chung, Hong Kong), AKTA FPLC system. The column was preequilibrated with 2 column vols buffer (50 mM sodium phosphate, 150 mM NaCl, pH 7.4). Then 0.5 mg protein in 500 lL was applied to the column, and 2 mL fractions were collected at a flow rate of 1 mLÆmin)1. The column was calibrated using appropriate molecular mass gel-filtration markers. Manchester, UK), fitted with a 337-nm laser. Protein [5 pmol in 0.5 lL 40% acetonitrile/0.1% trifluoroacetic acid (v/v)] was mixed with an equal volume of matrix [saturated solution of sinapinic acid in 40% acetonitrile/ 0.1% trifluoroacetic acid (v/v) in water] and applied to the MALDI target plate. This was allowed to dry at room temperature to form cocrystals of protein and matrix. BSA was used as an external mass standard. Single and double charged peaks arising from BSA were used for calibration. The operating parameters were: operating voltage, 20 kV; sampling rate, 500 MHz; sensitivity, 50 mV. Typically 20–25 scans were averaged to obtain the spectrum. Electrophoresis and Western blotting Primary sequences and 3D structure modeling Proteins were resolved on an SDS/12% polyacrylamide gel [21] and visualized by staining with Coomassie Brilliant Blue R-250. For Western blotting, crude cellular extracts and purified r-Pfen separated by SDS/PAGE (12% gel) were transferred to nitrocellulose membrane using semidry Western transfer apparatus (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at constant voltage (20 V) for 35 min. The membranes were blocked with 5% skimmed milk in phosphate buffered saline (NaCl/Pi; 137 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) containing 0.05% Tween 20 for 1 h. The blots were treated with the mouse anti-His serum and horseradish peroxidaseconjugated anti-mouse secondary IgG, respectively (1 : 1000 dilution for both). The immunoblots were developed using dianilinobenzene substrate. The enolase sequences were aligned using CLUSTAL W for homology comparisons [24]. The 3D structures of r-Pfen and rabbit muscle enolases were modeled according to the known 3D structure of T. brucei enolase (PDB:1OEP) published previously, using the SWISS-MODEL server [25] and structures were viewed with VIEWERPRO 5.0 (Accelerys, San Diego, CA, USA). Gel-filtration chromatography Protein measurements and enzyme assay Protein concentrations were determined by the Bradford method using Bio-Rad protein assay dye reagent with BSA as standard [22]. All kinetic measurements were made at 20 ± 1 C. Enolase activity was measured in the forward (formation of PEP from 2-PGA) and reverse (formation of 2-PGA from PEP) direction by monitoring the increase or decrease respectively in PEP absorbance at 240 nm in a continuous spectrophotometric assay on a Perkin-Elmer lambda 40 spectrophotometer. The change in PEP concentration was determined using an absorption coefficient (e240nm) ¼ 1400 M)1Æcm)1. As the absorption coefficient of PEP varies with pH and concentration of Mg2+, in experiments where pH or Mg2+ were varied, appropriate values of molar absorptivity for PEP were used [23]. Typically, 540 lL of assay mixture containing 1.5 mM 2-PGA (for the forward reaction) or 1.1 mM PEP (for the reverse reaction) and 1.5 mM MgCl2 in 50 mM Tris/HCl, pH 7.4, was used. One unit of enzyme was defined as the amount of enzyme that converts 1 lmol substrate (2-PGA or PEP) into product (PEP or 2-PGA) in 1 min at 20 C. Kinetic parameters were determined from [substrate] vs. velocity curves by fitting the data to the Michaelis–Menten equation using the SIGMAPLOT software. MALDI-TOF analysis For determination of the exact molecular mass of the expressed recombinant protein, MALDI-TOF mass spectra were recorded in linear mode on Tof-Spec 2E (Micromass, Reaction with thiol-modifying reagents r-Pfen or rabbit muscle enolase (0.1 lM) was placed in buffer (1 mM KH2PO4, 5 mM MgCl2, 0.1 mM dithiothreitol and 50 mM triethanolamine/HCl, pH 8.0) and incubated for 30 min at 37 C. Different amounts of iodoacetamide or N-ethylmaleimide were added to the enzyme samples and allowed to react at 37 C. Enzyme activity was assayed at different time intervals. Generation of antiserum and ELISA Standard protocols were followed to raise rabbit polyclonal antiserum [26]. Briefly, 500 lg r-Pfen was emulsified with Freund’s complete adjuvant and injected into a 2-monthold New Zealand White rabbit. Two boosts of 100 lg each of the r-Pfen emulsified with incomplete Freund’s adjuvant were given at an interval of 21 days. Ten days after the second booster, the rabbit serum was collected. All animal experiments were carried out as per the Guidelines of the Committee for the purpose of control and supervision of experiments on animals (CPCSEA), Animal Welfare Division, Government of India. The specific immunization experimental protocol was examined and cleared by the Institutional Animal Ethics Committee. For ELISA, the r-Pfen, rabbit muscle and yeast enolases were coated (100 lL of 0.6 lM per well) on a Maxisorp plate overnight at 4 C. Unbound antigen was removed by washing with NaCl/Pi. The wells were blocked with 5% skimmed milk in NaCl/Pi containing 0.05% Tween 20 (NaCl/Pi/Tween) for 1 h at 37 C. This was washed twice with NaCl/Pi/Tween. Antibodies raised in rabbit were diluted (2000–128 000-fold), and 100 lL of this was added to each well. Each dilution was coated in duplicates. This was allowed to bind to the antigens for 2 h at 37 C and then washed 6–7 times with NaCl/Pi/Tween. To this, goat antirabbit secondary IgGs conjugated with horseradish peroxidase (1 : 2000 dilution; 100 lL per well) in NaCl/Pi/Tween containing 0.01% BSA was added and allowed to incubate FEBS 2004 4848 I. Pal-Bhowmick et al. (Eur. J. Biochem. 271) for 45 min at 37 C. This was thoroughly washed with NaCl/Pi/Tween (7–8 times). Then 100 lL of 1 mgÆmL)1 2,2¢-azinobis(3-ethylbenzo-6-thiazolinesulfonic acid), prepared in 20 mM citrate/80 mM Na2HPO4, pH 4.3, containing 1 lLÆmL)1 30% H2O2, was added to each well and incubated for 10 min in the dark. The absorbance was read at 405 nm on an EL808 Ultra Microplate reader (Biotek Instruments Inc., Winooski, VT, USA). Indirect immunofluorescence assay An immunofluorescence assay was performed on the blood smears obtained from Plasmodium yoelii-infected mouse as described previously [27]. Briefly, the smears were fixed for 30 s using chilled methanol and treated with preimmune (control) or anti-(r-Pfen) serum at a dilution of 1 : 50 at room temperature for 1 h. This was then stained for 45 min with Alexa Fluor 488-conjugated anti-rabbit IgG. Parasite nuclei were stained with DAPI at a final concentration of 1 lgÆmL)1. The necessary washes were given after each antibody incubation step, and slides were mounted under glass coverslips in 5 lL vectashield mounting medium. Slides were examined using a Nikon fluorescence microscope. Results and Discussion Clone sequence and recombinant protein purification Native enolase from P. falciparum strain K1 [17] and strain 3D7 (NCBI: NP_700629) are predicted to contain 446 amino acids. The PCR amplification of the enolase gene from the gametocyte cDNA library of the NF54 strain of E. coli resulted in a fragment of the expected size of 1.4 kb. This fragment was cloned in pQE30 vector, and E. coli cells were transformed with the recombinant plasmid as described above (Materials and methods). The cloned gene was subjected to DNA sequencing, and the full amino-acid sequence of the recombinant protein was deduced. The amino-acid sequence was found to be identical with the 3D7 strain. However, these two strains differ from the K1 strain at position 131 in having an alanine residue in place of a proline. Figure 1 shows a comparison of amino-acid sequences of enolases from P. falciparum strains NF54 (this work), K1 [17] and P. yoelii (NCBI: AA1892). The pQE30 vector is specifically designed for the overexpression of heterologous proteins in E. coli. It allows the expression of the recombinant protein and results in the addition of a short noncleavable His tag sequence at its N-terminus. Cloning resulted in incorporation of an additional 18 (MRGSHHHHHHGSACELGT-) and seven (-LQPSLIS) residues to the N-terminus and C-terminus, respectively, of Pfen. This would yield a r-Pfen protein of mass 51 389.73 Da in contrast with 48 677 Da for the native enzyme. For purification of r-Pfen, typically 1 L culture was grown at 37 C, yielding 2 g wet cell pellet. Cells were lysed, and the extract was subjected to centrifugation to obtain soluble supernatant and pellet fractions. Both fractions contained r-Pfen (Fig. 2A, lanes 1 and 2). As the soluble fraction contained a decent amount of r-Pfen, recombinant protein was purified from this fraction by affinity chromatography using an agarose/Ni-nitrilotriacetic acid column as described in Materials and methods. As expected, most of the enolase bound to the resin, and a wash with 40 mM imidazole removed nonspecifically bound proteins (lanes 3 and 4 of Fig. 2A). Finally pure enolase P. falciparum NF54 ------MAHVITRINAR---EILDSRGNPTVEVDLETNLGIFRAAVPSGASTGIYEALEL 51 P. falciparum K1 ------MAHVITRINAR---EILDSRGNPTVEVDLETNLGIFRAAVPSGASTGIYEALEL 51 P. yoelii MLVKYWLASYFMIINPKNYEHIFYSRGNPTVEVDLETTLGIFRAAVPSGASTGIYEALEL 60 :* : **.: .*: *************.********************** P. falciparum NF54 RDNDKSRYLGKGVQKAIKNINEIIAPKLIGMNCTEQKKIDNLMVEELDGSKNEWGWSKSK 111 P. falciparum K1 RDNDKSRYLGKGVQKAIKNINEIIAPKLIGMNCTEQKKIDNLMVEELDGSKNEWGWSKSK 111 P. yoelii RDNDKSRYLGKGVQQAIKNINEIIAPKLIGLDCREQKKIDNMMVQELDGSKTEWGWSKSK 120 **************:***************::* *******:**:******.******** P. falciparum NF54 LGANAILAISMAVCRAGAAANKVSLYKYLAQLAGKKSDQMVLPVPCLNVINGGSHAGNKL 171 P. falciparum K1 LGANAILAISMAVCRAGAAPNKVSLYKYLAQLAGKKSDQMVLPVPCLNVINGGSHAGNKL 171 P. yoelii LGANAILAISMAICRAGAAANKTSLYKYVAQLAGKNTEKMILPVPCLNVINGGSHAGNKL 180 ************:******.**.*****:******::::*:******************* P. falciparum NF54 SFQEFMIVPVGAPSFKEALRYGAEVYHTLKSEIKKKYGIDATNVGDEGGFAPNILNANEA 231 P. falciparum K1 SFQEFMIVPVGAPSFKEALRYGAEVYHTLKSEIKKKYGIDATNVGDEGGFAPNILNANEA 231 P. yoelii SFQEFMIVPVGAPSFKEAMRYGAEVYHTLKSEIKKKYGIDATNVGDEGGFAPNILNAHEA 240 ******************:**************************************:** P. falciparum NF54 LDLLVTAIKSAGYEGKVKIAMDVAASEFYNSENKTYDLDFKTPNNDKSLVKTGAQLVDLY 291 P. falciparum K1 LDLLVTAIKSAGYEGKVKIAMDVAASEFYNSENKTYDLDFKTPNNDKSLVKTGAQLVDLY 291 P. yoelii LDLLVASIKKAGYENKVKIAMDVAASEFYNSETKTYDLDFKTPNNDKSLVKTGQELVDLY 300 *****::**.****.*****************.******************** :***** P. falciparum NF54 IDLVKKYPIVSIEDPFDQDDWENYAKLTAAIGKDVQIVGDDLLVTNPTRITKALEKNACN 351 P. falciparum K1 IDLVKKYPIVSIEDPFDQDDWENYAKLTAAIGKDVQIVGDDLLVTNPTRITKALEKNACN 351 P. yoelii IELVKKYPIISIEDPFDQDDWENYAKLTEAIGKDVQIVGDDLLVTNPTRIEKALEKKACN 360 *:*******:****************** ********************* *****:*** P. falciparum NF54 ALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAP 411 P. falciparum K1 ALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAP 411 P. yoelii ALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAP 420 ************************************************************ P. falciparum NF54 CRSERNAKYNQLLRIEESLGNNAVFAGEKFRLQLN 446 P. falciparum K1 CRSERNAKYNQLLRIEESLGNNAVFAGEKFRLQLN 446 P. yoelii CRSERNAKYNQLFRIEESLGANGSFAGDKFRLQLN 455 ************:******* *. ***:******* Fig. 1. Amino-acid sequence alignment of enolases from P. falciparum strain NF54 with P. falciparum strain K1 [17] and P. yoelli (NCBI:AA18892) using CLUSTAL W [24]. Enolase from strain NF54 differs from that of strain K1 in having a P131A mutation (shown in bold). FEBS 2004 Characterization of P. falciparum enolase (Eur. J. Biochem. 271) 4849 M 1 2 3 4 5 1 2 3 4 5 kDa 205 116 97 66 50 kDa 45 29 Fig. 2. Analysis of proteins from transformed E. coli XL1 Blue cells over-expressing r-Pfen. Cells were induced with 0.5 mM isopropyl thio-b-Dgalactoside for 6 h and harvested. (A) Analysis on SDS/PAGE (12% gel). Lane M, Molecular mass markers; lanes 1 and 2, insoluble and soluble fractions, respectively, of the E. coli extract; lane 3, flow through after binding of the r-Pfen supernatant fraction to Ni-nitrilotriacetic acid; lane 4, 40 mM imidazole wash of the protein bound to Ni-nitrilotriacetic acid resin; lane 5, elution of r-Pfen with 250 mM imidazole. (B) Immunoblot of cells over-expressing r-Pfen probed with 1 : 1000 anti-His serum. The arrow shows the position of r-Pfen. Oligomeric state of r-Pfen The oligomeric state of r-Pfen was examined by gel-filtration chromatography. Figure 3 shows an elution profile of 0.5 mg r-Pfen in 500 lL 50 mM sodium phosphate/150 mM NaCl, pH 7.4, on a Superdex-75 column. The column was calibrated using appropriate molecular mass markers. The apparent molecular mass determined for native r-Pfen was 100 kDa. Purified r-Pfen when analyzed on SDS/PAGE showed a single band at 50 kDa (Fig. 2A, lane 5), indicating that it forms a homodimer in the native state. It is also interesting to note that, in the MALDI-TOF spectrum, a peak was observed at m/z 102 782 corresponding to a singly charged dimeric form of r-Pfen. Enolases from most organisms form dimers of 40–50-kDa subunits [10,12], exception for octameric enolases from thermophilic [12] and sulfate-reducing bacteria [28]. The oligomeric state of none of the apicomplexan enolases has been reported so far. Kinetic characterization Purified r-Pfen was assayed for enolase activity by measuring either the conversion of 2-PGA into PEP (forward reaction) or PEP into 2-PGA (reverse reaction). The enzyme had a specific activity of 30 ± 3 UÆ(mg protein))1 in the forward direction and 10 ± 2 UÆmg)1 in the reverse direction. For the determination of Km, initial reaction rates were measured at several different concentrations of 2-PGA (Fig. 4A) and PEP (Fig. 4B). Data were fitted to the 30 OD280 (mAU) protein was eluted with 250 mM imidazole. The eluted protein showed a single band at the expected molecular mass ( 50 kDa) on SDS/PAGE (Fig. 2A, lane 5). The identity of the protein was further established by Western blotting using anti-His serum (Fig. 2B). About 50 mg active r-Pfen was purified from 1 L E. coli culture. The molecular mass of the recombinant protein was also analyzed by MS. The MALDI-TOF spectrum of purified r-Pfen contained three peaks at m/z 25707, 51 383.04 and 102 782. The peak at m/z 51 383.04 can be attributed to a singly charged monomeric species of r-Pfen, which is in good agreement with the calculated average mass of 51 389.73 Da. The peak at m/z 25 707 represents a doubly charged monomeric species, and the one at m/z 102 782 is attributed to the presence of a singly charged dimeric species of r-Pfen. The r-Pfen sequence gave a theoretical absorption coefficient (e280) of 41400 M)1Æcm)1. The concentration of purified r-Pfen determined by Bradford assay using BSA as standard was in good agreement with that obtained by measuring A280 and using the theoretical absorption coefficient. 20 10 0 40 50 60 70 Elution Volume (ml) 80 90 Fig. 3. Gel-filtration chromatogram of r-Pfen. Protein (0.5 mg in 500 lL) was run on a Superdex-75 column precalibrated using appropriate molecular mass markers (chymotrypsinogen A, 25 kDa; ovalbumin, 43 kDa; BSA, 67 kDa; yeast enolase, 93 kDa; alcohol dehydrogenase, 150 kDa). Blue Dextran 2000 was used to measure the void volume. The molecular mass obtained for r-Pfen from this experiment was 98 ± 5 kDa. FEBS 2004 4850 I. Pal-Bhowmick et al. (Eur. J. Biochem. 271) 50 40 B 40 Activity (milliUnits) Activity (milliUnits) A 30 20 10 30 20 10 0 0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 0.0 [2-PGA](mM) 20 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 [PEP](mM) 25 C D 20 Activity (milliUnits) Activity (milliUnits) 18 16 14 12 10 8 6 15 10 5 0 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2 pH 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 pH Fig. 4. Kinetic characterization of r-Pfen. (A) Plot of [2-PGA] vs. activity; and (B) plot of [PEP] vs. activity for the determination of Km. A 5 lL sample of enzyme containing 1.5 and 3.0 lg of r-Pfen, respectively, were used for the 2-PGA and PEP assay, respectively. Experimental data were fitted according to the Michaelis–Menten equation using SIGMAPLOT. The best fit gave Km2PGA ¼ 0.041 ± 0.004 mM and KmPEP ¼ 0.25 ± 0.03 mM. pH was plotted against activity using (C) 2-PGA and (D) PEP as substrates. A 5 lL sample of enzyme containing 0.5 lg r-Pfen was used for the 2-PGA assay and 2.5 lg was used for the PEP assay. Michaelis–Menten equation {v ¼ Vmax[S]/(Km + [S])} using SIGMAPLOT software. The best nonlinear fit gave Km2PGA ¼ 0.041 ± 0.004 mM and KmPEP ¼ 0.25 ± 0.03 mM. These values for Km2PGA and KmPEP are similar to those reported for mammalian, yeast and other enolases [18]. The variation of r-Pfen activity as a function of pH was also analysed. Figure 4C,D shows plots of enzyme activity vs. pH when 2-PGA or PEP was used as substrate. Maximal r-Pfen activity is observed in the range pH 7.4–7.6 irrespective of the substrate used. Most mammalian enolases have their activity maxima in the range pH 6.8–7.1, whereas the plant ones are around pH 8.0 [10]. The effect of univalent cations on the activity of r-Pfen was also investigated. Figure 5A shows the variation in r-Pfen activity with increasing concentrations of NaCl and KCl. NaCl inhibits the enzyme with 50% inhibition around 0.3–0.4 M. This inhibitory effect of Na+ is very similar to that observed for mammalian enolases [14]. In contrast, KCl showed a slight activating effect on r-Pfen. The activity of all three rabbit isozymes (aa, bb and cc) are significantly stimulated (40–100%) by KCl at lower concentrations (< 400 mM), whereas in the higher concentration range the activation effect is lost [14]. KCl has a mild activating effect on yeast enolase at concentrations < 200 mM, but strongly inhibits activity at higher concentrations [14]. This kinetic response of r-Pfen to various concentrations of KCl is at variance to those of mammalian and yeast enolases. Figure 5B shows the effect of increasing concentrations of Mg2+ on the activity of r-Pfen, rabbit and yeast enolases. In the low concentration range, Mg2+ acts as an activating cofactor for all the enolases. Data from the low concentration range (£ 1 mM) were fitted to the Michaelis–Menten equation to derive the apparent activation coefficient. The activation constant derived for r-Pfen from the data presented here is 0.18 ± 0.02 mM. Higher concentrations of Mg2+ have an inhibitory effect on r-Pfen activity. The maximal inhibition observed for r-Pfen is much less (< 40%) than that observed for the yeast and rabbit muscle enzymes (60–70%) (Fig. 5B). Previous kinetic studies have suggested the presence of three bivalent cationbinding sites on enolase, with the first two high-affinity sites involved in activation and a third low-affinity site involved in inhibition [13]. In the crystal structure, two Mg2+-binding sites have been detected. These are believed to be involved in assembly of the active site and catalysis [29,30]. Recently, a third bivalent cation-binding site has been identified in the structure of T. brucei enolase. It has been suggested that binding of Mg2+ at this site may be FEBS 2004 Characterization of P. falciparum enolase (Eur. J. Biochem. 271) 4851 A B Fig. 5. Effect of univalent and bivalent cations on r-Pfen activity. (A) Effect of NaCl (d) and KCl (s). Data are plotted as percentage activity vs. [salt]. A 540 lL volume of assay mixture containing 1.1 mM PEP and 1.5 mM MgCl2 in 50 mM Tris/HCl, pH 7.4, was used. A 5 lL volume of enzyme solution containing 2.5 lg enolase protein was used for each assay. (B) A comparison of the effect of MgCl2 on the activity of r-Pfen (d), yeast enolase (s) and rabbit muscle enolase (.). The assay mixture consisted of 1.1 mM PEP in 50 mM Tris/HCl, pH 7.4. The residual activity in the absence of Mg2+ is due to contaminating bivalent cations in the assay mixture. For comparison, data for each enzyme were normalized taking highest observed activity as 100%. responsible for the observed inhibition at high metal ion concentrations [19]. Homology-based structure modeling Enolase is highly conserved across species. The overall structure of enolase comprises an eightfold a/b barrel domain preceded by an N-terminal a + b domain [19]. A highly conserved catalytic site is located between the two domains. It will be interesting to model the parasite enzyme on the basis of the known enolase structure and examine the structural differences between Pfen and the mammalian enzyme in the vicinity of the conserved active site. Such an exercise may lead to identification of parasite-specific residue(s), which may be amenable to specific chemical modifications and hence selective inactivation. We modeled the 3D structure of r-Pfen and rabbit muscle enzymes on the basis of T. brucei enolase (PDB: 1OEP) which is 60% homologous to Pfen. Figure 6 shows the active-site regions of these enzymes along with some of the residues in the vicinity. In a recent study on the T. brucei enzyme, it was shown that modification of Cys241 and Cys147 with iodoacetamide leads to partial inactivation of the Trypanosoma enzyme [18,19]. This inactivation was attributed to the perturbation caused to active-site structure by the addition of a carboxamidomethyl group to Cys147 and/or Cys241. Analogous positions in Pfen are occupied by Ala251 and Cys157. Ala148 replaces Cys157 in Pfen in rabbit muscle enolase. It will be interesting to examine the effect of thiolmodifying regents on r-Pfen. It is expected that similar to Cys147 in T. brucei, Cys157 in Pfen will be carboxamidomethylated, causing partial inactivation. As the rabbit enzyme does not have a similar Cys, it may not be affected. To determine whether Cys157 is accessible to chemical modification, which may lead to inactivation (similar to T. brucei [19]), we treated the enzyme with iodoacetamide (Fig. 6D). There was no effect on the activity of r-Pfen even after 2 h of treatment with 10 mM iodoacetamide. As expected, the addition of iodoacetamide to rabbit muscle enolase also did not have any effect on the activity. Although Cys157 occupies a position similar to Cys147 in T. brucei (Fig. 6A,B), the microenvironment in the two cases may be quite different. It is likely that either the Cys157 is not accessible to iodoacetamide or the carboxamidomethyl group fits into the cavity around the Cys without any perturbation of the arrangement of the active-site residues. The latter possibility would suggest that the use of larger thiol-modifying reagents (e.g. N-ethylmaleimide) might lead to inactivation. In the case of T. brucei enolase, complete inactivation by N-ethylmaleimide has been observed [19]. The addition of N-ethylmaleimide to r-Pfen did lead to partial inactivation of the enzyme (Fig. 6D). However, similar inactivation was also observed for rabbit enolase, which does not have analogous Cys157 near the active site (Fig. 6C), suggesting that N-ethylmaleimideinduced inactivation is probably due to modification of other Cys residues in the protein. Although these preliminary attempts have not succeeded in achieving speciesspecific inactivation, efforts will be made to design substrate-based active-site-directed affinity reagent(s) for selective inactivation of the parasite enzyme. Reactivity and specificity of anti-(r-Pfen) evaluated by ELISA Antibodies raised in rabbit after two boosts of r-Pfen protein showed quite high titer and reactivity with r-Pfen. Reactivity was observed even at a dilution of > 64 000 (Fig. 7A). In comparison, when equimolar quantities of rabbit muscle and yeast enolases were used as antigens, almost no significant reactivity was observed beyond an antiserum dilution of 1 : 16 000. To rule out the possibility that this antiserum may contain a significant fraction of antibodies directed against the His6 tag of r-Pfen, we used an unrelated His6-tagged protein (rOS-F, a recombinant odorant-binding protein from Drosophila) as control. No significant cross-reactivity was observed against this protein (data not shown). Although there is 61–68% homology FEBS 2004 4852 I. Pal-Bhowmick et al. (Eur. J. Biochem. 271) A C B D 120 % Activity 100 80 60 40 20 0 20 40 60 Time (min) 80 100 Fig. 6. Comparison of the active-site regions of (A) T. brucei (PDB code 1OEP), (B) P. falciparum and (C) rabbit muscle enolase. P. falciparum and rabbit muscle (P25704; ENOB_rabbit) enolases were modeled using the T. brucei X-ray crystallographic structure. Residues involved in substrate and metal binding are shown in green and magenta, respectively. (D) Effect of iodoacetamide (open symbols) and N-ethylmaleimide (filled symbols) on r-Pfen (circles) and rabbit muscle enolase (squares). Enolase (20 lg) was incubated with 10 mM iodoacetamide or 8 mM N-ethylmaleimide. Enzyme activity was assayed at various time points. among yeast, rabbit and P. falciparum enolases, the polyclonal antibodies raised here exhibit considerably higher specificity for r-Pfen. We further assessed the specificity of the antiserum by performing an indirect immunofluorescence assay on blood smears obtained from P. yoelii-infected mice. The gene sequences of enolase from murine malarial parasite, P. yoelii and P. falciparum, exhibit 90% identity and 94% similarity in their amino-acid sequences (Fig. 1). On the basis of such a large sequence homology, it is expected that polyclonal antibodies raised against r-Pfen would cross-react with the P. yoelii enolase protein. As shown in Fig. 7B, the immune serum reacted with the parasite-infected mouse red blood cells and not with uninfected red blood cells. The parasiteinfected cells can be identified by using DAPI staining. As uninfected red cells do not have a nucleus, they do not pick up DAPI. DAPI-positive cells (parasite-infected) are the only ones stained by anti-(r-Pfen). All the erythrocytic stages of the parasite (rings, trophozoites and schizonts) reacted to anti-(r-Pfen). A control immunofluorescence assay experiment was also performed using preimmune rabbit serum. As expected, no staining of the parasite-infected cells was observed (Fig. 7C). These experiments also demonstrate that anti-(r-Pfen) sera did not have any cross-reactivity towards the mammalian red blood cell enolase protein. Conclusions We have cloned and developed an over-expression system for P. falciparum enolase. This has allowed us to obtain decent amounts of pure protein (50–60 mg per litre of culture). The measured physicochemical parameters (molecular mass and absorption coefficient at 280 nm) for the expressed protein are in good agreement with those predicted on the basis of the cloned sequence. The presence of a 50-kDa band on SDS/ PAGE for purified r-Pfen and 100 kDa on gel-filtration FEBS 2004 Characterization of P. falciparum enolase (Eur. J. Biochem. 271) 4853 and the fact that they fail to react with mammalian enolases (Fig. 7B). This recombinant protein is highly immunogenic, as only two booster doses were sufficient to give titers of > 1 : 64 000 for specific reactivity with the antigen. This polyclonal antibody is being used to investigate subcellular localization of enolase at different stages in the life cycle of the parasite. The availability of large quantities of r-Pfen will also facilitate structural investigations on this apicomplexan glycolytic enzyme. 2.0 A 405 nm 1.6 a 1.2 b 0.8 c 0.4 Acknowledgements 0.0 2,000 4,000 8,000 16,000 32,000 64,000 128,000 Antiserum (fold dilution) We are grateful to Dr Nirbhay Kumar of Johns Hopkins University, Baltimore, MD, USA for the gift of k Orient P. falciparum strain NF54 gametocyte asexual stage library. We thank Mr Prateek Gupta and Mr Yogesh Gupta for help with some of the experiments. References a: anti-r-pfen a: pre-immune b: DAPI b: DAPI Fig. 7. Specificity of polyclonal antibodies raised against r-Pfen in rabbit. (A) ELISA reactivity of anti-(r-Pfen) with (a) r-Pfen, (b) rabbit muscle enolase and (c) yeast enolase, measured as A405 and plotted against increasing dilutions of antibody. (B) Immunofluorescence assay with P. yoelii-infected mouse red blood cells treated with (a) anti-(r-Pfen) serum (1 : 50 dilution) and (b) DAPI (1 lgÆmL)1). (C) P. yoelii-infected cells were treated with (a) preimmune sera (1 : 50 dilution) and (b) DAPI (1 lgÆmL)1). chromatography suggests that, in its native state, r-Pfen forms an active homodimer similar to the enolases from several other sources [10,12]. This is further supported by the presence of a peak at m/z 102 782 in the MALDI spectrum. Kinetic measurements showed substrate affinity to be similar to that of mammalian enolases. r-Pfen differs from rabbit enolases in its extent of inhibition caused by high Mg2+ concentration (Fig. 5B) and inability of K+ to activate it significantly (Fig. 5A) [14]. Although enolases from rabbit muscle and P. falciparum exhibit a high degree of sequence homology (67–69%), antibodies raised against r-Pfen in rabbit are quite specific, as evident from ELISA (Fig. 7A) 1. Engers, H.D. & Godal, T. (1998) Malaria vaccine development: current status. Parasitol. Today 14, 56–64. 2. Oelshlegel, F.J. Jr & Brewer, G.J. (1975) Parasitism and the red cell. In The Red Cell (Surgenor, D.M., ed.), Vol. 2, pp. 1264. Academic Press, San Diego. 3. Trager, W. (1986) Metabolism: Energy Sources, Respiration. In Living Together: the Biology of Animal Parasitism, pp. 147–169. Plenum Press, New York. 4. Roth, E.F. Jr, Raventos-Suarez, C., Perkins, M. & Nagel, R.L. (1982) Glutathione stability and oxidative stress in P. falciparum infection in vitro; responses of normal and G6PD-deficient cells. Biochem. Biophys. Res. Commun. 109, 355–362. 5. Certa, U., Ghersa, P., Dobel, H., Matile, H., Kocher, H.P., Shrivastava, I.K., Shaw, A.R. & Perrin, L.H. (1988) Aldolase activity of a Plasmodium falciparum protein with protective properties. Science 240, 1036–1038. 6. Gomez, M.S., Piper, R.C., Hunsaker, L.A., Royer, R.E., Deck, L.M., Makler, M.T. & Vander Jagt, D.L. (1997) Substrate and cofactor specificity and selective inhibition of lactate dehydrogenase from the malarial parasite P. falciparum. Mol. Biochem. Parasitol. 90, 235–246. 7. Piper, R., Lebras, J., Wentworth, L., Hunt-coole, A., Houze, S. & Makler, M. (1999) Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase. Am. J. Trop. Med. Hyg. 60, 109–118. 8. Velankar, S.S., Ray, S.S., Gokhale, R.S., Suma, S., Balaram, H., Balaram, P. & Murthy, M.R.N. (1997) Triosephosphate isomerase from Plasmodium falciparum: the crystal structure provides insights into antimalarial drug design. Structure 5, 751–761. 9. Pancholi, V. (2001) Multifunctional a-enolase: its role in diseases. Cell. Mol. Life Sci. 58, 902–920. 10. Wold, F. (1971) Enolase. In The Enzymes (Boyer, P.D., ed.), Vol. 5, pp. 499–538. Academic Press, New York. 11. Barnes, L.D. & Stellwagen, E. (1973) Enolase from the thermophile Thermus X-1. Biochemistry 12, 1559–1565. 12. Brown, C.K., Kuhlman, P.L., Mattingly, S., Slates, K., Calie, P.J. & Farrar, W.W. (1998) A model of quaternary structure of enolases, based on structural and evolutionary analysis of octameric enolase from Bacillus subtilis. J. Protein Chem. 17, 855– 866. 13. Faller, L.D., Baroudy, B.M., Jonson, A.M. & Ewall, R.X. (1977) Magnesium ion requirements for yeast enolase activity. Biochemistry 16, 3864–3869. 14. Kornblat, M.J. & Klugerman, A. (1989) Characterization of the enolase isozymes of rabbit brain: kinetic differences between mammalian and yeast enolases. Biochem. Cell Biol. 67, 103–107. 4854 I. Pal-Bhowmick et al. (Eur. J. Biochem. 271) 15. Sato, K., Kano, S., Matsumoto, Y., Glanarongran, R., Krudsood, S., Looareesuwan, S., Aikawa, M. & Suzuki, M. (1998) Serological evaluation of malaria patient in Thailand, with particular reference to the reactivity against a 47kD antigenic polypeptide of Plasmodium falciparum. Tokai J. Exp. Clin. Med. 23, 97–98. 16. Roth, E.F. Jr, Calvin, M.C., Max-Audit, I., Rosa, J. & Rosa, R. (1988) The enzymes of the glycolytic pathway in erythrocytes infected with Plasmodium falciparum malaria parasites. Blood 72, 1922–1925. 17. Read, M., Hicks, K.E., Sims, P.F.G. & Hyde, J.E. (1994) Molecular characterization of the enolase gene from the human malaria parasite Plasmodium falciparum. Eur. J. Biochem. 220, 513–520. 18. Hannaert, V., Albert, M.-A., Rigden, D.J., da Silva, Giotto, M.T., Thiemann, O., Garratt, R.C., Van Roy, J., Opperdoes, F.R. & Michels, P.A.M. (2003) Kinetic characterization, structure modelling studies and crystallization of Trypanosoma brucei enolase. Eur. J. Biochem. 270, 3205–3213. 19. da Silva. Giotto, M.T., Hannaert, V., Vertommen, D., de Navarro, M.V.A.S., Rider, M.H., Michels, P.A.M., Garratt, R.C. & Rigden, D.J. (2003) The crystal structure of Trypanosoma brucei enolase: visualization of the inhibitory metal binding site III and potential as target for selective, irreversible inhibition. J. Mol. Biol. 331, 653–665. 20. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 21. Laemmli, U.K. (1970) Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nature (London) 227, 680–685. FEBS 2004 22. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254. 23. Wold, F. & Ballou, C.E. (1957) Studies on the enzyme enolase I. Equilibrium studies. J. Biol. Chem. 227, 301–312. 24. Thompson, J.D., Higgins, D.G. & Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673– 4680. 25. Guex, N. & Peitsch, M.C. (1997) SWISS-MODEL and the Swiss Pdb viewer: an environment for comparative protein modeling. Electrophoresis 18, 2714–2723. 26. Harlow, E.D. & Lane, D. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 27. Goswami, A., Singh, S., Redkar, V.D. & Sharma, S. (1997) Characterization of P0, a ribosomal phosphoprotein of Plasmodium falciparum. J. Biol. Chem. 272, 12138–12143. 28. Kitamura, M., Takayama, Y., Kojima, S., Kohno, K., Ogata, H., Higuchi, Y. & Inoue, H. (2004) Cloning and expression of the enolase gene from Desulfovibrio vulgaris (Miyazaki F). Biochim. Biophys. Acta 1676, 172–181. 29. Wedekind, J.E., Poyner, R.R., Reed, G.H. & Rayment, I. (1994) Chelation of serine 39 to Mg2+ latches a gate at the active-site of enolase: structure of the bis (Mg2+) complex of yeast enolase and the intermediate analog phosphoacetohydroxamate at 2.1 Å resolution. Biochemistry 33, 9333–9342. 30. Kuhnel, K. & Luisi, B.F. (2001) Crystal structure of the Escherichia coli RNA degradosome component enolase. J. Mol. Biol. 313, 583–592.